Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit
June 18, 2024 16:30 ET
|
Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024 16:05 ET
|
Tenaya Therapeutics, Inc.
Initial Data from Ongoing MyPEAK™-1 Phase 1b of TN-201 Expected in Second Half of 2024 Clinical Sites Activated for RIDGE™-1 Phase 1b Clinical Trial of TN-401 Announced Cost Containment Measures in...
Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting
May 02, 2024 17:00 ET
|
Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 08:30 ET
|
Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences
September 21, 2023 16:05 ET
|
Tenaya Therapeutics, Inc.
TN-301 First-in-Human Phase 1 Clinical Trial Results and Preclinical Combination Data to be Presented at Heart Failure Society of America Annual Scientific Meeting TN-201 Interim Seroprevalence Study...
Imbria Pharmaceuticals Completes Enrollment in the Phase 2 IMPROVE-ISCHEMIA Clinical Trial of Ninerafaxstat in Patients with Stable Angina
August 16, 2023 08:00 ET
|
Imbria Pharmaceuticals Inc.
– IMPROVE-ISCHEMIA, a randomized, placebo-controlled trial, with topline data expected in 4Q 2023 – – Additional Phase 2 data read-outs expected in 4Q 2023, including topline from the IMPROVE-HCM...
Worldwide Precision Cardiology Industry to 2027 - by Offering, Sample Type, Technology, Application, End-user and Region
October 26, 2022 07:48 ET
|
Research and Markets
Dublin, Oct. 26, 2022 (GLOBE NEWSWIRE) -- The "Global Precision Cardiology Market: Competition Forecast and Opportunities to 2027" report has been added to ResearchAndMarkets.com's offering.The...
Global Precision Cardiology Industry 2021-2031: Focus on Offering, Sample, Technology, Application, End-user, and Region
February 28, 2022 06:28 ET
|
Research and Markets
Dublin, Feb. 28, 2022 (GLOBE NEWSWIRE) -- The "Precision Cardiology Market - A Global and Regional Analysis: Focus on Offering, Sample, Technology, Application, End User, and Region - Analysis and...
Healthtech Solutions, Inc. (HLTT), Parent Company of Cutting-Edge Medical Technology Companies, Files Reg A With SEC
March 17, 2021 08:30 ET
|
Healthtech Solutions, Inc.
March 8, 2021, filing to raise up to $75 million. Maximum of 1,500,000 shares of Series B preferred stock offered at price of $50 per share.Healthtech Solutions, Inc. is organized to pursue...
Cardiomyopathy Medication Market To Reach USD 1,148.9 Million By 2026 | Reports And Data
November 04, 2019 12:11 ET
|
Reports and Data
New York, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Rising prevalence of cardiomyopathy diseases, new product development for targeted cardiac illnesses, collaborations for medical advancements and...